S Percy Ivy Selected Research

tanespimycin (17AAG)

4/2012	A phase I trial of docetaxel and pulse-dose 17-allylamino-17-demethoxygeldanamycin in adult patients with solid tumors.
2/2012	A phase II study of gemcitabine in combination with tanespimycin in advanced epithelial ovarian and primary peritoneal carcinoma.
11/2011	Phase I and pharmacological study of cytarabine and tanespimycin in relapsed and refractory acute leukemia.
6/2011	Phase I study of 17-allylamino-17 demethoxygeldanamycin, gemcitabine and/or cisplatin in patients with refractory solid tumors.
12/2008	A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer.
6/2008	A phase I study of 17-allylamino-17-demethoxygeldanamycin combined with paclitaxel in patients with advanced solid malignancies.
4/2007	Evaluation of plasma insulin-like growth factor binding protein 2 and Her-2 extracellular domain as biomarkers for 17-allylamino-17-demethoxygeldanamycin treatment of adult patients with advanced solid tumors.
3/2007	Phase I pharmacokinetic and pharmacodynamic study of 17-N-allylamino-17-demethoxygeldanamycin in pediatric patients with recurrent or refractory solid tumors: a pediatric oncology experimental therapeutics investigators consortium study.
3/2007	Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer.
3/2007	Phase I and pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with refractory advanced cancers.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

S Percy Ivy Research Topics

Disease

78	Neoplasms (Cancer) 10/2022 - 11/2003
8	Ovarian Neoplasms (Ovarian Cancer) 09/2019 - 10/2014
7	Fatigue 01/2019 - 05/2005
5	Hypertension (High Blood Pressure) 12/2018 - 05/2010
3	Prostatic Neoplasms (Prostate Cancer) 01/2019 - 12/2008
3	Diarrhea 12/2018 - 05/2005
3	Glioblastoma (Glioblastoma Multiforme) 01/2017 - 11/2013
3	Pancreatic Neoplasms (Pancreatic Cancer) 08/2014 - 06/2011
2	Adenocarcinoma 01/2021 - 04/2009
2	Melanoma (Melanoma, Malignant) 01/2021 - 04/2013
2	Leukopenia 01/2019 - 01/2017
2	Neutropenia 01/2019 - 10/2013
2	Vulvar Neoplasms (Vulvar Cancer) 11/2017 - 01/2017
2	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 03/2016 - 04/2014
2	Renal Cell Carcinoma (Grawitz Tumor) 11/2014 - 08/2013
2	Liver Diseases (Liver Disease) 07/2013 - 02/2008
2	Carcinoma (Carcinomatosis) 02/2012 - 04/2009
2	Leukemia 11/2011 - 11/2003
2	Disease Progression 10/2010 - 03/2007
2	Vomiting 03/2007 - 05/2005
2	Nausea 03/2007 - 05/2005
1	Hematologic Neoplasms (Hematological Malignancy) 10/2022
1	Triple Negative Breast Neoplasms 01/2022
1	Hairy Cell Leukemia 01/2021
1	T-Cell Lymphoma (Lymphoma, T Cell) 10/2020
1	Peritoneal Diseases 01/2020
1	Ataxia Telangiectasia (Louis Bar Syndrome) 09/2019
1	Methemoglobinemia 01/2019
1	Vaginal Neoplasms (Cancer, Vaginal) 01/2019
1	Chronic Disease (Chronic Diseases) 11/2018
1	Uterine Cervical Neoplasms (Cancer of the Cervix) 01/2018
1	Carcinogenesis 01/2017
1	Thrombocytopenia (Thrombopenia) 01/2017
1	Dyspnea (Shortness of Breath) 01/2017

Drug/Important Bio-Agent (IBA)

13	cediranib (AZD2171)IBA 01/2021 - 08/2010
12	tanespimycin (17AAG)IBA 04/2012 - 05/2005
10	Pharmaceutical PreparationsIBA 10/2022 - 05/2005
8	3-aminopyridine-2-carboxaldehyde thiosemicarbazone (triapine)IBA 01/2019 - 10/2010
7	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 01/2021 - 08/2010
7	Ribonucleotide Reductases (Ribonucleotide Reductase)IBA 09/2019 - 06/2013
7	Biomarkers (Surrogate Marker)IBA 01/2019 - 04/2007
6	Proteins (Proteins, Gene)FDA Link 05/2015 - 11/2003
5	PlatinumIBA 01/2022 - 02/2013
5	olaparibIBA 01/2021 - 10/2014
5	Cisplatin (Platino)FDA LinkGeneric 01/2019 - 06/2011
5	Gemcitabine FDA Link 08/2014 - 06/2011
5	Heat-Shock Proteins (Heat-Shock Protein)IBA 11/2011 - 11/2003
4	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2022 - 01/2016
4	Investigational DrugsIBA 09/2019 - 03/2010
4	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2019 - 05/2010
4	Oxaliplatin (Eloxatin)FDA LinkGeneric 02/2013 - 02/2009
3	Phosphotransferases (Kinase)IBA 01/2021 - 11/2003
3	Angiogenesis InhibitorsIBA 09/2019 - 11/2014
3	Biological ProductsIBA 01/2019 - 10/2010
3	Docetaxel (Taxotere)FDA Link 01/2019 - 04/2012
3	Amyloid Precursor Protein Secretases (beta-Secretase)IBA 05/2015 - 10/2013
3	2,2- dimethyl- N- (6- oxo- 6,7- dihydro- 5H- dibenzo(b,d)azepin- 7- yl)- N'- (2,2,3,3,3- pentafluoropropyl)malonamideIBA 05/2015 - 10/2013
3	Irinotecan (Camptosar)FDA LinkGeneric 10/2010 - 02/2009
2	ibrutinibIBA 01/2021 - 01/2021
2	Interleukin-2 (IL2)IBA 01/2021 - 04/2013
2	DNA (Deoxyribonucleic Acid)IBA 09/2019 - 01/2017
2	ElectrolytesIBA 01/2019 - 01/2017
2	Tyrosine Kinase InhibitorsIBA 01/2019 - 07/2010
2	Antineoplastic Agents (Antineoplastics)IBA 11/2016 - 04/2006
2	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 01/2016 - 01/2015
2	Cytotoxins (Cytolysins)IBA 10/2015 - 01/2009
2	Sunitinib (Sutent)FDA Link 11/2014 - 05/2011
2	pazopanib FDA Link 07/2013 - 07/2010
2	EnzymesIBA 08/2010 - 03/2007
2	Capecitabine (Xeloda)FDA Link 04/2009 - 02/2009
2	Imatinib Mesylate (Gleevec)FDA Link 02/2008 - 02/2008
1	trametinibIBA 02/2022
1	veliparibIBA 01/2022
1	purineIBA 01/2021
1	RNA (Ribonucleic Acid)IBA 01/2021
1	Agammaglobulinaemia Tyrosine KinaseIBA 01/2021
1	romidepsin (FK228)FDA Link 10/2020
1	AZD4547IBA 01/2020
1	NucleotidesIBA 01/2020
1	Fibroblast Growth Factor Receptors (Fibroblast Growth Factor Receptor)IBA 01/2020
1	CyclinsIBA 09/2019
1	Protein Kinases (Protein Kinase)IBA 09/2019
1	Prostate-Specific Antigen (Semenogelase)IBA 01/2019
1	Prednisone (Sone)FDA LinkGeneric 01/2019
1	rucaparibIBA 12/2017
1	DeoxyribonucleotidesIBA 01/2017
1	Choline (Choline Chloride)IBA 01/2017
1	Indicators and Reagents (Reagents)IBA 01/2017
1	Temozolomide (Temodar)FDA LinkGeneric 01/2017
1	CreatineIBA 01/2017
1	Pemetrexed (MTA)FDA Link 04/2016
1	Adenosine Diphosphate (ADP)IBA 01/2016

Therapy/Procedure

38	Therapeutics 10/2022 - 10/2005
8	Drug Therapy (Chemotherapy) 10/2022 - 04/2013
4	Immunotherapy 10/2021 - 01/2016
3	Radiotherapy 01/2020 - 04/2006
1	Contraception (Birth Control) 10/2021
1	Investigational Therapies (Experimental Therapy) 01/2021
1	Stem Cell Transplantation 11/2018
1	Chemoradiotherapy 01/2018